1 / 55

PRACTICAL PSYCHIATRY FOR PRIMARY CARE

PRACTICAL PSYCHIATRY FOR PRIMARY CARE. THE MEDICAL MANAGEMENT OF MAJOR DEPRESSIVE DISORDER Hisam S. Goueli, M. D. Assistant Professor – Department of Psychiatry and Behavioral Sciences Emory University. MAJOR DEPRESSION BASICS. COMMON second leading cause of worldwide disability

fedora
Download Presentation

PRACTICAL PSYCHIATRY FOR PRIMARY CARE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PRACTICAL PSYCHIATRY FOR PRIMARY CARE THE MEDICAL MANAGEMENT OF MAJOR DEPRESSIVE DISORDER Hisam S. Goueli, M. D. Assistant Professor – Department of Psychiatry and Behavioral Sciences Emory University

  2. MAJOR DEPRESSION BASICS • COMMON • second leading cause of worldwide disability • thirty-five percent meet criteria for depression • five to thirteen percent suffer from major depression • BURDEN • economic costs – absenteeism and presenteeism • medical costs – higher morbidity and mortality

  3. MAJOR DEPRESSION BASICS • PRIMARY CARE VERSUS PSYCHIATRY • USPSTF and ACPM: category B • patient numbers – more than 50% • medical comorbidity • clinical outcomes • power of Family Medicine

  4. MAJOR DEPRESSION DIAGNOSIS • DSM-IV-TR (2000) and DSM-V (2013) • two week history of change from baseline • depressed mood or anhedonia • four or more supporting criteria – suicide aside • not general medical condition or substance • not misdiagnosed for different psychiatric condition • significant distress or impairment

  5. MAJOR DEPRESSION DIAGNOSIS • FREQUENCY: Single versus Recurrent • seventy-five to eighty-five percent are recurrent • two episodes spaced by 2 months • elimination of chronic modifier • SEVERITY: Mild, Moderate and Severe • COMPLEXITY: Psychosis and Catatonia • mood-congruent versus mood-incongruent • Three of twelve catatonic symptoms

  6. MAJOR DEPRESSION TOOLS: DISEASE EDUCATION

  7. MAJOR DEPRESSION TOOLS: DISEASE EDUCATION LOSS EXISTENTIAL STRESS RESILIENCE DEVELOPMENT BIOLOGICAL

  8. MAJOR DEPRESSION TOOLS: DISEASE EDUCATION

  9. MAJOR DEPRESSION TOOLS: DISEASE EDUCATION

  10. MAJOR DEPRESSION TOOLS: DEFINITIONS

  11. MAJOR DEPRESSION TOOLS: DEFINITIONS

  12. MAJOR DEPRESSION TOOLS: INVENTORIES • BASIC TWO QUESTION SCREEN • down, depressed or hopeless • little interest or pleasure doing things • ADVANCED INVENTORIES • Beck Depression Inventory (BDI-II) • Patient Health Questionnaire-9 (PHQ-9) • Quick Inventory of Depressive Symptomatology – Self Report (QIDS-SR) • Reynolds Adolescent Depression Scale (RADS) • Geriatric Depression Scale (GDS)

  13. MAJOR DEPRESSION TREATMENT: MEDICATION OVERVIEW • BIOLOGICAL TREATMENT DEVELOPMENT • first generation – increase concentrations • second generation – selective • third generation – combination • SECRET REGARDING ANTIDEPRESSANTS • Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

  14. MAJOR DEPRESSION: BRIEF SUMMARY • DIAGNOSIS OF MAJOR DEPRESSION • MAJOR DEPRESSION FIVE “R”s • response versus remission • relapse, reoccurrence and recovery • THE MONOAMINE HYPOTHESIS • serotonin and norepinephrine • monoamine deficiencies

  15. MAJOR DEPRESSION TREATMENT: MEDICATION OVERVIEW

  16. MAJOR DEPRESSION TREATMENT: MEDICATION OVERVIEW • FACTORS AFFECTING DECISION • prior response, family response and patient choice • medical and psychiatric comorbid conditions • cost • pharmacokinetics • gender, race and ethnicity • adherence and tolerability

  17. MAJOR DEPRESSION TREATMENT: MEDICATION OVERVIEW • ANTIDEPRESSANT GUIDELINES • thirty percent placebo response • low initial dosages with methodical titration • reevaluate at 4 weeks • full therapeutic between 6 to 12 weeks

  18. MAJOR DEPRESSION TREATMENT: MEDICATION OVERVIEW • ANTIDEPRESANT DURATION • minimum of 6-8 months after recovery • visits 1-3 months • slow taper over 2-3 months • long term management

  19. MAJOR DEPRESSION TREATMENT: ENZYME INHIBITORS • MONOAMINE INHIBITORS • 3 available medications – phenelzine, tranylcypromine and isocarboxacid • most effective and most risky • fatal dietary restriction and drug interactions • STAR*D: incorporated at last stage

  20. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • SELECTIVE SEROTONIN (SSRIs) • SEROTONIN AND NOREPINEPHRINE (SNRIs) • TRICYCLIC ANTIDEPRESSANTS (TCAs) • ATYPICAL AGENTS

  21. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) • six available choices • first line – replaced tricyclic antidepressants • STAR*D: 47% achieved remission

  22. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • SELECTIVE SEROTONIN SIMILARITIES • potent serotonin reuptake inhibition • side effect profiles – serotonin projections • SELECTIVE SEROTONIN DIFFERENCES • pharmacokinetics • cytochrome P450 profiles • secondary pharmacological characteristics • tolerability

  23. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION

  24. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION AKATHISIA, AGITATION and OBSESSIONS MOOD LIMBIC: ANXIETY GUT: CRAMPS and DIARRHEA APPETITE and EATING SEXUAL BEHAVIOR, VOMITTING and SLEEP

  25. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION

  26. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • SELECTIVE SEROTONIN MANAGEMENT • maximum dosages – no fear dosing • adequate medication trials • side effect education – gastrointestinal and sexual • discontinuation – 20% per week reductions • serotonin withdrawal -- FLUSH

  27. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • SEROTONIN WITHDRAWL -- FLUSH • F: flu-like symptoms • L: lightheadedness and dizziness • U: uneasiness • S: sleep disturbances • H: headaches

  28. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) • 3 available choices • first or second line therapy – safer than TCAs • STAR*D: remission rates similar to SSRIs

  29. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION NRI SNRI SRI

  30. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION MOOD, INFORMATION PROCESSING and ATTENTION HEART: TACHYCARDIA ENERGY, FATIGUE and PSYCHOMOTOR TREMOR BLOOD PRESSURE

  31. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION

  32. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) • activity depends on dose • maximum dosages – no fear dosing • adequate medication trials • side effect education – hypertension (3-13%) • pain syndromes – fibromyalgia and neuropathic pain

  33. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • TRICYCLIC ANTIDEPRESSANTS • 9 available agents • two major flavors – tertiary and secondary amines • replaced secondary to safety and tolerability • STAR*D: equal to mirtazipine

  34. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION NRI CONSTIPATION, BLURRED VISION, DRY MOUTH and DROWSINESS WEIGHT GAIN and DROWSINESS TCA HIST MUSC SRI DIZZINESS and DECREASED BLOOD PRESSURE ALPHAS

  35. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • NORTRIPTYLINE – 25mg to 150mg • secondary amine – less affinity for alpha, histamine and muscarinic receptors • blood levels guide dose • low therapeutic index • caution populations – arrhythmias, sinus node dysfunction, conduction defects, dementia, suicidal patients and elderly

  36. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION • ATYPICAL AGENTS • 3 available agents • two groups – norepinephrine and dopamine reuptake inhibitors (NDRIs) and mixed action • STAR*D: NDRIs remission similar to SSRIs • mixed action covered in anxiety lecture

  37. MAJOR DEPRESSION TREATMENT: REUPTAKE INHIBITION

  38. MAJOR DEPRESSION TREATMENT: NEGATIVE FEEDBACK INHIBITORS • MIRTAZIPINE – 7.5mg to 45mg • alpha-2 antagonist: cuts off the breaks • histimine blockade: sedation and weight gain • STAR*D: same as nortriptyline

  39. MAJOR DEPRESSION TREATMENT: BASICS CONCLUSION • DIAGNOSIS OF MAJOR DEPRESSION • MAJOR DEPRESSION FIVE “R”s • response versus remission • relapse, reoccurrence and recovery • BASIC MEDICATION MANAGEMENT • selective serotonin • serotonin and norepinephrine • tricyclic antidepressants • atypical agents

  40. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION • IMPORTANCE OF REMISSION • eighty percent rule • obstacles to remission

  41. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION SWITCHING AUGMENTATION

  42. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION • SWITCHING • stop and start – MAOIs • dual tapering – third generation antidepressants • simultaneous switching – SSRIs • SWITCHING GROUND RULES • fifty percent response per SSRI • washout periods for MAOIs – 2 to 5 weeks

  43. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION • AUGMENTATION ADVANTAGES • decrease relapse • synergistic neurotransmitter effect • AUGMENTATION DISADVANTAGES • increase side effects • increase pharmacokinetic interactions • increase medication complexity and compliance

  44. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION • COGNITIVE-BEHAVIORAL AUGMENTATION • MEDICATION AUGMENTATION • S: stimulants • A: atypical antipsychotics • L: lithium • T: triiodothyronine (T3)

  45. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION • SOMATIC AUGMENTATION • Electroconvulsive Therapy (ECT) • Vagal Nerve Stimulators (VNS) • Trans Magnetic Stimulators (TMS) • Deep Brain Stiumlators (DBS)

  46. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION

  47. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION

  48. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION • STIMULANTS • increase dopamine and norepinephrine • patient selection • alertness and improved cognition • cautions • discontinuation

  49. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION • ATYPICAL ANTIPSYCHOTICS • serotonin2C receptor antagonism • patient selection • metabolic side effects and seizure risk • choosing an antipsychotic • discontinuation

  50. MAJOR DEPRESSION ADVANCED:SWITCHING AND AUGMENTATION • LITHIUM • potentiates serotonergic activity • patient selection • response rates – onset and overall • practical family medicine evaluation and dosing • treatment failure – serum level 0.6 for 6 weeks

More Related